Ajinomoto Bio-Pharma Services wurde mit drei „CDMO Leadership Awards“ ausgezeichnet
March 14, 2023 – (San Diego, CA, Tokyo, Japan and Wetteren, Belgium) – Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, received three CDMO Leadership Awards in the categories Capabilities, Compatibility, and Expertise in both the Overall and Big Pharma respondent groups.
Established in 2011, the CDMO Leadership Awards recognize top outsourcing partners. The awards, rebranded from the CMO Leadership Awards, are presented by Life Science Leader magazine and Industry Standard Research. 72 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. Based on ratings of these recent outsourced projects provided by sponsors, this experiential feedback is analyzed by sponsor company size to reveal leading CMOs in different performance categories.
“For over a decade, these awards have been the most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, ISR Reports, which only surveys drug sponsors who have worked directly and recently with specific CDMOs, ensures the validity of these results. Our winners are your gold-medalists of outsourcing.” Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
“We are proud to be recognized by our partners as we continue to invest in new technologies, quality systems, and facilities to increase our capabilities and expertise to meet the needs of our clients. We take pride in knowing our efforts are helping countless patients for years to come.” Said Yasuyuki Otake, General Manager, Bio-Pharma Services Department.
Über Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services ist ein vollintegriertes Auftragsentwicklungs- und Produktionsunternehmen mit Standorten in Belgien, den Vereinigten Staaten, Japan und Indien, das umfassende Dienstleistungen in den Bereichen Entwicklung, cGMP-konforme Herstellung sowie aseptische Abfüllung und Verpackung für klein- und großmolekulare Wirkstoffe und Zwischenprodukte anbietet. Ajinomoto Bio-Pharma Services bietet eine breite Palette innovativer Plattformen und Kompetenzen für präklinische und Pilotprogramme bis hin zu kommerziellen Mengen, darunter die Corynex®-Proteinexpressionstechnologie, Oligonukleotidsynthese, Antikörper-Wirkstoff-Konjugate (ADC), hochwirksame Wirkstoffe (HPAPI), Biokatalyse, kontinuierliche Durchflussfertigung und vieles mehr. Ajinomoto Bio-Pharma Services hat es sich zur Aufgabe gemacht, ein hohes Maß an Qualität und Service zu bieten, um den Bedürfnissen unserer Kunden gerecht zu werden. Erfahren Sie mehr: www.AjiBio-Pharma.com
